Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of Roflumilast in Hyperinflated COPD Patients Using Functional Respiratory Imaging

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patient ≥ 30 years old~* Written informed consent obtained~* Patient with Body mass index (BMI) ≥ 20~* Female patient of childbearing potential who confirm that a contraception method was used at least 14 days before visit 1 and will continue to use a contraception method during the study~* COPD patient with GOLD stages C and D~* Patient with a Borg Fatigue score after the 6MWT on screening above 4 to indicate the susceptibility to dynamics hyperinflation~* Patient with smoking history of at least 10 pack-years~* Patient takes a combination therapy of LABA/ LAMA at least 6 weeks before visit 1~* Patient must be able to understand and complete the protocol requirements, instructions, questionnaires and protocol-stated restrictions~Exclusion Criteria:~* Pregnant or lactating females~* Patient with severe immunological diseases and/ or severe acute infectious diseases~* Patient with heart failure as documented in the medical history or as defined by the investigator during the physical examination performed at visit 1~* Patient with diagnosis of cancer (except basal cell carcinoma)~* Patient with a history of depression associated with suicidal ideation or behaviour~* Patient with moderate or severe hepatic impairment.~* Patient with lactose intolerance~* Patient is unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study.~* Patient who received inhalation corticosteroids (ICS) within the last 6 weeks prior to the screening visit~* Patient who received any investigational new drug within the last 4 weeks prior to the screening visit or twice the duration of the biological effect of any drug (whichever is longer)

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Roflumilast (Type: ACTIVE_COMPARATOR): Patient will take Roflumilast (500 micrograms) once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months of treatment
- Placebo (Type: PLACEBO_COMPARATOR): Patient will take the Placebo of Roflumilast once a day for 3 months. A HRCT scan will be taken at baseline and after 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).